Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) EV-to-FCF: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09637 Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
5 GF Score
Price HK$25.00
! 1 Warning Sign
View Full Analysis

What is Alebund Pharmaceuticals (Jiangsu) EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alebund Pharmaceuticals (Jiangsu)'s Enterprise Value is HK$8,988.26 Mil. Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF at this moment.

The historical rank and industry rank for Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF or its related term are showing as below:

HKSE:09637' s EV-to-FCF Range Over the Past 10 Years
Min: -20.89   Med: 0   Max: 0
Current: -19.41
HKSE:09637's EV-to-FCF is ranked worse than
100% of 568 companies
in the Drug Manufacturers industry
Industry Median: 20.11 vs HKSE:09637: -19.41

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-10), Alebund Pharmaceuticals (Jiangsu)'s stock price is HK$25.00. Alebund Pharmaceuticals (Jiangsu) does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Alebund Pharmaceuticals (Jiangsu)'s PE Ratio (TTM) at this moment.

Alebund Pharmaceuticals (Jiangsu)  (HKSE:09637) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alebund Pharmaceuticals (Jiangsu)'s PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.00/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Alebund Pharmaceuticals (Jiangsu) EV-to-FCF Related Terms

Alebund Pharmaceuticals (Jiangsu) EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alebund Pharmaceuticals (Jiangsu) EV-to-FCF Chart

Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend Dec24 Dec25
EV-to-FCF
0.00 0.00

Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Dec24 Dec25
EV-to-FCF 0.00 0.00

HKSE:09637 vs LLY, JNJ, ABBV: EV-to-FCF Comparison

For the Drug Manufacturers - General subindustry, Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alebund Pharmaceuticals (Jiangsu) EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF falls into.


HKSE:09637
5GF Score
Alebund Pharmaceuticals (Jiangsu) Ltd HKSE:09637
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alebund Pharmaceuticals (Jiangsu) EV-to-FCF Calculation

Alebund Pharmaceuticals (Jiangsu)'s EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8988.258/
=

Alebund Pharmaceuticals (Jiangsu) Business Description

Address No. 7 Jinzhuang Road, Building 7, High-tech Zone, Gaoxin District, Hanjiang District, Jiangsu Province, Yangzhou, CHN
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score

Get the complete analysis for HKSE:09637

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$25.00
Price